Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alector Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALEC
Nasdaq
8731
https://alector.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alector Inc
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
- Apr 25th, 2024 2:02 pm
The past five years for Alector (NASDAQ:ALEC) investors has not been profitable
- Apr 11th, 2024 2:26 pm
The Alector, Inc. (NASDAQ:ALEC) Full-Year Results Are Out And Analysts Have Published New Forecasts
- Mar 1st, 2024 11:45 am
What You Need To Know About The Alector, Inc. (NASDAQ:ALEC) Analyst Downgrade Today
- Feb 29th, 2024 10:41 am
Q4 2023 Alector Inc Earnings Call
- Feb 28th, 2024 7:02 pm
Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 3:13 pm
Alector to Participate in Upcoming Healthcare Conferences
- Feb 28th, 2024 12:00 pm
Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 9:46 pm
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Feb 27th, 2024 9:05 pm
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
- Feb 20th, 2024 9:05 pm
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
- Feb 20th, 2024 3:00 pm
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
- Feb 8th, 2024 12:00 pm
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
- Feb 8th, 2024 11:48 am
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
- Feb 7th, 2024 12:00 pm
With 67% institutional ownership, Alector, Inc. (NASDAQ:ALEC) is a favorite amongst the big guns
- Feb 1st, 2024 10:43 am
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
- Jan 25th, 2024 5:00 pm
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
- Jan 23rd, 2024 12:32 pm
Alector Announces Closing of Public Offering
- Jan 19th, 2024 2:20 pm
Alector Announces Pricing of Public Offering of Common Stock
- Jan 17th, 2024 1:54 pm
Alector Announces Proposed Public Offering of Common Stock
- Jan 16th, 2024 9:01 pm
Scroll